Prolactinoma drug doses face off: which is better for your metabolism?
NCT ID NCT07045935
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how different doses of the drug cabergoline affect blood sugar control in people with prolactinoma, a type of pituitary tumor. Researchers will randomly assign 60 adults to different treatment strategies and measure their glucose levels after a sugar drink. The goal is to find the best dose to manage the tumor while keeping metabolism healthy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabergoline (a dopamine agonist drug)
What this could lead to
If successful, this trial could help doctors choose the best cabergoline dose to manage prolactinoma while minimizing negative effects on blood sugar.
What could go wrong
This is a small, early-phase trial (60 people) comparing different doses of an existing drug, not testing a new cure. Results may not apply to all patients, and cabergoline can cause side effects like nausea or dizziness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLACTINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Basel, Dept. of Endocrinology, Metabolism & Diabetes
RECRUITINGBasel, 4031, Switzerland
Contact Email: •••••@•••••
Contact